Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human mutant tissue-type plasminogen activator
- Development stage
- Unknown
- Lead developer
- Beijing World Trade Dongrui Pharmaceutical Technology
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant human mutant tissue-type plasminogen activator (rhM-tPA) is an investigational thrombolytic biologic developed by Beijing World Trade Dongrui Pharmaceutical Technology. It is a genetically modified version of the endogenous human tissue-type plasminogen activator (tPA), a serine protease responsible for converting plasminogen into plasmin to dissolve fibrin-based blood clots. rhM-tPA is engineered to allow for administration as a single intravenous bolus, which may provide a clinical advantage over the standard-of-care alteplase (rt-PA) that typically requires an initial bolus followed by a continuous infusion. The drug is primarily being developed for the treatment of acute ST-segment elevation myocardial infarction (STEMI) and has been evaluated in Phase II clinical trials to compare its efficacy and safety against alteplase.
- Other names
- rhM-tPArecombinant human mutant tissue-type plasminogen activator
02
Targets
PAI-1 (Plasminogen activator inhibitor type 1)PLG (Plasminogen)Fibrin (Factor Ia)
Beyond the preview
Go deeper on recombinant human mutant tissue-type plasminogen activator.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human mutant tissue-type plasminogen activator.